Cargando…

Relationship between UGT1A16/28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy

PURPOSE: A retrospective study was performed to analyze the relationship between uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *6/*28 gene polymorphisms and adverse reactions associated with irinotecan (CPT-11)-based chemotherapy. The correlation between UGT1A1 polymorphisms and the clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Yu, Wu, Hai-wei, Ma, Xu, Liu, Ying, Zhang, Yan-hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488790/ https://www.ncbi.nlm.nih.gov/pubmed/28790841 http://dx.doi.org/10.2147/OTT.S137644

Ejemplares similares

Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy
por: Liu, Xing-Han, et al.
Publicado: (2017)

Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens
por: Yang, Chen, et al.
Publicado: (2015)

Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
por: Liu, X, et al.
Publicado: (2014)

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer
por: Fukuda, Minoru, et al.
Publicado: (2017)

The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
por: Su, Y.-Y., et al.
Publicado: (2022)

UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan
por: Kimura, Kei, et al.
Publicado: (2018)

Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis
por: Atasilp, Chalirmporn, et al.
Publicado: (2022)

Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
por: Zhu, Xiaoqin, et al.
Publicado: (2021)

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
por: Takano, Masashi, et al.
Publicado: (2017)

Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1(*)6 or UGT1A1(*)28
por: Tian, Chuan, et al.
Publicado: (2018)

Association between UGT1A1*28 Polymorphisms and Clinical Outcomes of Irinotecan-Based Chemotherapies in Colorectal Cancer: A Meta-Analysis in Caucasians
por: Liu, Xiang, et al.
Publicado: (2013)

Impact of UGT1A1 genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer
por: Iwasa, Satoru, et al.
Publicado: (2021)

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray
por: Tsunedomi, Ryouichi, et al.
Publicado: (2017)

Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis
por: Zhu, Xiaoyun, et al.
Publicado: (2020)

Rapid detection of the irinotecan‐related UGT1A1*28 polymorphism by asymmetric PCR melting curve analysis using one fluorescent probe
por: Kong, Xiaomu, et al.
Publicado: (2022)

Polymorphisms of UGT1A1(*)6, UGT1A1(*)27 & UGT1A1(*)28 in three major ethnic groups from Malaysia
por: Teh, L. K., et al.
Publicado: (2012)

Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism
por: Jannin, Arnaud, et al.
Publicado: (2017)

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
por: Fujii, Hironori, et al.
Publicado: (2018)

Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang
por: Chen, Shaojun, et al.
Publicado: (2020)

Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous UGT1A1*28 polymorphism: a single-center case series
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis
por: Liu, Dan, et al.
Publicado: (2017)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
por: Lee, Lawrence Soon-U, et al.
Publicado: (2016)

The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer
por: Xiao, Xiao-guang, et al.
Publicado: (2015)

Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Amandito, Radhian, et al.
Publicado: (2019)

Dosage Adjustment of Irinotecan in Patients with UGT1A1 Polymorphisms: A Review of Current Literature
por: Argevani, Lia, et al.
Publicado: (2020)

Commentary: Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Heydari, Mohammad Reza, et al.
Publicado: (2020)

Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1 * 28 or * 6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A)
por: Fukuda, Minoru, et al.
Publicado: (2016)

A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes
por: TSUNEDOMI, RYOUICHI, et al.
Publicado: (2014)

Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer
por: Li, Minmin, et al.
Publicado: (2014)

UGT1A1(*)28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
por: Kweekel, D M, et al.
Publicado: (2008)

Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain
por: Bravo-Gómez, Adrián, et al.
Publicado: (2022)

Association of gallstone and polymorphisms of UGT1A1*27 and UGT1A1*28 in patients with hepatitis B virus-related liver failure
por: Zhuo, Haiyan, et al.
Publicado: (2022)

Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai
por: Cai, Xun, et al.
Publicado: (2013)

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
por: Marcuello, E, et al.
Publicado: (2004)

UGT1A1 Allele Test Not Only Minimizes the Toxicity But Also Maximizes the Therapeutic Effect of Irinotecan in the Treatment of Colorectal Cancer: A Narrative Review
por: Li, Yaoyuan, et al.
Publicado: (2022)

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
por: Hsieh, Yi-Chien, et al.
Publicado: (2021)

The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients
por: Lee, Choong-kun, et al.
Publicado: (2022)

Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
por: Maeda, Hiromichi, et al.
Publicado: (2014)

Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1
por: Wang, Lingzhi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a9oj63dnish4s9p6vp4daslpu9